V
Voyager Therapeutics, Inc. (VYGR)
NMS – Real Time Price. Currency in USD
3.59
+0.04 (1.13%)
At close: Jun 26, 2026, 4:00 PM EDT
3.65
+0.06 (1.67%)
After-hours: Jun 26, 2026, 6:42 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
3.59
+0.04 (1.13%)
At close: Jun 26, 2026, 4:00 PM EDT
3.65
+0.06 (1.67%)
After-hours: Jun 26, 2026, 6:42 PM EDT
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease. The company also provides research program for the treatment of Huntington’s disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
| Name | Position |
|---|---|
| Dr. Alfred W. Sandrock Jr., M.D., Ph.D. | President, CEO & Director |
| Dr. Krystof Bankiewicz M.D., Ph.D. | Founder |
| Dr. Mark A. Kay M.D., Ph.D. | Founder |
| Dr. Mathieu Nonnenmacher Ph.D. | Vice President of Gene Therapy |
| Mihalis Kariolis | Vice President of Non-Viral Therapeutics |
| Mr. Gregory Shiferman | Senior VP, General Counsel & Secretary |
| Mr. Todd Carter Ph.D. | Chief Scientific Officer |
| Ms. Amy Quinlan | Principal Accounting Officer |
| Ms. Robin Swartz | Principal Financial Officer, Treasurer, Chief Business Officer & COO |
| Ms. Trista Morrison | Chief Corporate Affairs Officer & Chief of Staff to the CEO |
| Date | Type | Document |
|---|---|---|
| 2026-06-10 | 8-K | tm2617230d1_8k.htm |
| 2026-06-01 | 8-K | tm2616041d1_8k.htm |
| 2026-05-07 | 8-K | vygr-20260507x8k.htm |
| 2026-05-07 | 10-Q | vygr-20260331x10q.htm |
| 2026-04-28 | DEFA14A | tm2611464d3_defa14a.htm |
| 2026-04-28 | DEF 14A | tm2611464-4_def14a.htm |
| 2026-04-28 | ARS | tm2611466d2_ars.pdf |
| 2026-04-21 | 8-K | tm2612325d1_8k.htm |
| 2026-04-10 | PRE 14A | tm2611464-1_pre14a.htm |
| 2026-03-09 | 8-K | vygr-20260309x8k.htm |